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Ointments containing paromomycin (PA) have been used for
topical treatment of cutaneous leishmaniasis. Although influence
of the vehicle on skin permeation is crucial for optimization of
formulations containing PA, this aspect has not been investigated
experimentally. In this study, we have evaluated the influence of
the formulation type [oil-in-water (o/w), water-in-oil-in-water
(w/o/w) emulsions and ointment] on in vitro release and skin
permeation of PA and experiments were carried out on cellulose
acetate membrane and skin biopsies from hairless mice, respectively.
PA release from o/w emulsion (51.7% ± 0.9 of dose applied) was
faster than that observed for w/o/w emulsion (3.0% ± 0.5). PA
absorption from o/w emulsion (87.1% ± 3.9) through stripped skin
was 5 to 6 times higher than that observed for w/o/w multiple
emulsion (14.7% ± 0.5) and ointment (16.6% ± 0.1). PA permeation
through intact (normal) skin was negligible for all tested
formulations. Skin uptake from o/w emulsion (0.9% ± 0.1) was
greater than that observed for w/o/w multiple emulsion (0.3% ±
0.1) and ointment (0.1% ± 0.1). These results suggest that a
hydrophilic vehicle (o/w emulsion) could be an interesting
alternative to improve topical delivery of PA.
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Tegumentary leishmaniasis is a complex group of
diseases caused by various different Leishmania species.
Each species is responsible for a certain group of clinical
symptoms, which can vary from the presence of single
localized ulcers (cutaneous leishmaniasis) to the diffuse or
the disfiguring mucocutaneous forms of the disease
(Barral-Neto et al., 1995).
Currently, pentavalent antimonials, administered
parenterally, are considered the first line drugs in treatment
of cutaneous leishmaniasis. This treatment causes a
variety of side effects, including changes in the
electrocardiogram and increase of hepatic transaminases.
Thus, many alternative systemic and topical treatments
have been used to treat cutaneous leishmaniasis
(Grevelink, Lerner, 1996).
As an alternative treatment, local therapy can be
of value because of its simple administration, safety and
fewer side effects. Paromomycin sulphate (PA), a
aminoglycoside antibiotic, has demonstrated a high in
vitro activity against Leishmania major amastigotes in
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macrophages (El-On, Greenblat, 1983; Neal et al.,
1995).
In experimental models and clinical studies, El-On et
al. (1984, 1986, 1988) have been demonstrated that an
ointment containing 15% PA and 12% methylbenzethonium
chloride (MBCL), a quaternary ammonium surfactant, was
effective against L. major. The local side effects due to
MBCl (Berman, 1997) have led to development of a
formulation containing PA and urea as skin penetration
enhancer of the drug (Neal et al., 1994). This ointment
cured all L. major lesions on Balb/C mice, however clinical
trials carried out in Tunisia (Salah et al., 1995) and in Iran
(Asilian et al., 1995) suggest that this formulation was not
as effective as that containing PA/MBCl. The modification
of the vehicle (base) could be also an alternative approach
to enhance the anti-leishmanial activity of PA.
Although it is well established that the vehicle greatly
influences drug percutaneous absorption, this aspect has
not been experimentally investigated for the topical
application of PA. The vehicle can influence drug
absorption both by changing the stratum corneum
permeability or the thermodynamic activity of the drug
(Moser et al., 2001; Lalor, Flynn, Weiner, 1994, 1995).
Thus, the aim of this study was to investigate, by the first
time, the influence of the vehicle on in vitro release and
skin permeation of PA from emulsions and an ointment.
Since the cutaneous leishmaniasis lesions often
develop into an ulcer without stratum corneum (Grevelink,
Lerner, 1996; Neal et al., 1994), the principal barrier for
skin penetration, a vehicle-controlled delivery system
(w/o/w multiple emulsion) containing PA was also
developed. The skin permeation and release of glucose, as
hydrophilic drug model, from w/o/w emulsion was
prolonged when compared with that obtained with an o/w
emulsion (Ferreira et al. ,  1995). Thus, the three




Paromomycin sulfate (PA), potency of 718 mg/g,
was donated by Pharmacia & Upjohn (Milan, Italy). The
surfactants used were: a silicone-based polymeric
lipophilic surfactant (Abil EM90®; HLB=3) obtained from
Goldschmidt (France) and a hydrophilic surfactant, a block
copolymer of ethylene and propylene oxide (Synperonic
PEF/127®; HLB=18-23) donated by ICI Surfactants
(Belgium). Paraffin oil and soft white paraffin were
obtained from Favab (Brazil). All other chemicals used
were analytical reagent grade.
Methods
Preparation of the formulations
In order to investigate only the influence of the
emulsion type, w/o/w multiple and o/w simple emulsions
were prepared according to the same formula. It was si-
milar to that described previously (Ferreira et al., 1994,
1995): 22% of paraffin oil, 3% of lipophilic surfactant, 1%
of hydrophilic surfactant, 1% of paromomycin sulfate
(PA) and 73% of 0.08 M NaCl, by weight. However,
procedures of emulsification were different.
W/o/w multiple emulsion was prepared by a two-
stage emulsification procedure. In the first step, a w/o
primary emulsion was formed by adding the aqueous
phase to oily phase at 8,000 rpm for 30 minutes.
Emulsification was carried out using a ULTRA TURRAX
T-25 type agitator (IKA, Staufen, Germany). In a second
step, w/o primary emulsion was dispersed to external
aqueous phase using an EUROSTAR basic agitator (IKA,
Staufen, Germany) at 400 rpm for 15 minutes (Table I).
O/w emulsion was prepared through the addition of
the aqueous phase to oily phase at 8,000 rpm for 15
TABLE I - Composition (% w/w) of the w/o/w multiple emulsion
Steps Phase Components % w/w
First Oily Oila 30
w/o emulsion Hydrophobic surfactantb 4
inner aqueous NaCl 0.08M 64.7
Paromomycin 1.3
Second w/o emulsion 75
w/o/w emulsion external aqueous Hydrophilic surfactantc 25
aParaffin oil; ba silicone-based polymeric hydrophobic surfactant (Abil EM90®; HLB=3); ca block copolymer of ethylene
and propylene oxide (Synperonic PEF/127®; HLB=18-23).
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minutes. Emulsification was carried out using an ULTRA
TURRAX T-25® agitator at 25 ºC. Ointment was
prepared by triturating PA into soft white paraffin until a
homogeneous mixture has been obtained.
Characterization of the emulsions
After preparation, microscopic observations
(Olympus-Micronal, Brazil) and conductivity values
(Conductivity Meter Micronal B-330, Brazil) confirmed that
two emulsion types (w/o/w or o/w) were obtained.
Percentage of PA entrapped in internal phase of the
w/o/w emulsion was determined through the difference
between total and encapsulated PA content. To determi-
ne total PA content, samples of 100 mg of the multiple
emulsions were diluted with 100 mL of distilled water and
extracted with three 40-mL quantities of chloroform.
Chloroform was discarded and PA concentration in
aqueous solution was determined by microbiologic assay
(see below). Not encapsulated PA content was
determined after dilution of samples (100 mg) in 25 mL of
an aqueous solution of glucose at same osmolarity as that
of the internal aqueous phase. Aliquots were filtered
through Millipore filter (0.45 mm) and PA concentration
was determined by microbiologic assay.
In vitro release of PA
In vitro release of PA was determined in modified
Franz diffusion cells, as described previously (Ferreira et
al., 1995). Briefly, cellulose acetate membranes (thickness:
25 ±1 mm; MWC 5.000; Dianorm - Munique) were placed
horizontally dividing the cell in two compartments: the
donor and the receptor. Receptor compartment was filled
with 0.05 M phosphate buffered (pH 7.4) saline. This re-
ceptor liquid, maintained at 37 oC, was continually stirred
with a small magnetic bar.
These experiments were carried out in infinite dose
and the donor compartment was covered with Parafilm®
(American National Can, Greenwich, CT). Preparations
were applied (500 mg) and serial sampling was performed
at specific times by totally removing receptor fluid and
refilling with fresh solution. PA concentration was
determined by microbiologic assay (see below).
In vitro skin permeation
In vitro skin permeation through dorsal skin excised
from hairless mice was determined with the same Franz
cells described above. Male, 8 weeks old hairless mice
(strain HRS/J Jackson Laboratories, Bar Harbor, ME)
were sacrificed by cervical rupture and the dorsal skin was
used immediately. These experiments were made in the
presence or absence of the stratum corneum (SC). SC was
removed by stripping 5 times with a cellophane tape
(SCOTH Magic no 810, 3M). Receptor compartment was
filled with 0.05M phosphate buffered saline (pH 7.4).
Donor compartment was left open and preparations
(50 mg), containing 1% w/w of PA, were applied on the skin
and spread with a glass rod. Serial sampling was performed
as described above.
At the end of the experiments, removal of the excess
formulation was determined by washing and rinsing of the
treated surface twice times with 500 µL of liquid cleansing
soap at 5% (Extrán®, Merk) and twice times with 500 µL
of water, removing the residue with a cotton swab.
Washing solvent, pipette tips and cotton swab were added
to a bottle containing 100 mL of distilled water. PA
concentration in this solution was determinated by
microbiologic assay. Thus, recovery from ointment was of
95.5% ± 2.2 of the dose applied. PA remaining into skin
(dermis + epidermis) was extracted as follows: skin
biopsies were vortex-mixed for 15 minutes in distilled water
(2 mL); samples were centrifuged and supernatant
fractions were filtered through Millipore filter (0.45 mm).
PA concentration was determined by microbiologic assay.
Formulations without PA were also submitted to all
protocols described previously. These samples did not
interfered with the analysis method.
Microbiologic assay of the PA
Microbiological assays are traditionally used for
determination of aminoglycoside antibiotics. Assay of PA
was made according methodology described in United
States Pharmacopoeia (USP 23, 1995). Briefly,
concentration of PA was determined by an agar-diffusion
inhibition assay of the growth of a test organism,
Staphylococcus epidermidis (ATCC 12,228). Diffusion
of PA in agar resulted in an inhibition halo that represented
the absence of growth of the microorganism. A linear
relationship between diameter of the inhibition halo and
logarithm of the PA concentration was observed. PA
concentration was determined from a standard curve
(y = 9.9417x + 8.5568; R2 = 0.9988).
Statistical Analysis
Analysis of variance (ANOVA) was used to
evaluate differences between means. Differences at level
pd”0.05 were considered significant.
RESULTS AND DISCUSSION
The aim of this study was to evaluate the influence
of the vehicle on topical delivery of PA. Therefore,
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membrane of cellulose acetate was used only as a
preliminary step to studies that will include in vitro skin
permeation. This synthetic membrane has been used as in
vitro release method for creams, ointments and gels based
on the principle that the effectiveness of topical products
is dependent on the release of active drug from its dosage
form (Shah, Skelly, 1993).
Release of PA from o/w simple emulsion (51.7% ±
0.9 of the applied dose) was considerably greater than that
observed from w/o/w multiple emulsion (3.0% ± 0.5).
When half of the amount of PA was added to external
aqueous phase of the w/o/w multiple emulsion (w/o/wPA),
released amount was intermediary (26.2% ± 0.4) in
comparison with other preparations (Figure 1).
High release from o/w emulsion can be attributed to
availability of PA in aqueous phase of this emulsion. Lalor,
Flynn, Weiner (1994, 1995) showed that, in an emulsion,
interaction of the drug between water and oil phase can
determine extent of lowering of the thermodynamic activity
in external phase which is in contact with membrane.
Partitioning of PA into internal oily phase or its micelar
solubilization in external phase of the o/w emulsion is
unlikely, due to hydrophilic characteristic of the drug.
The extremely slow release of PA from the multiple
emulsion can be explained by the fact that diffusion of PA
through oily phase is the limiting step for drug release.
Percentage of PA entrapped in internal aqueous phase of
the W/O/W emulsion was high (91.3%), whereas the PA
percentage in external aqueous phase was low (8.7%).
Only this content of PA in external phase would be
immediately available for release. A similar phenomenon
has been observed for glucose from multiple emulsion
(Ferreira et al., 1995). This hypothesis is also supported by
the fact that PA release from w/o/wPA was greater than
that observed from w/o/w multiple emulsion, once that a
larger amount of drug is available in external phase.
In order to validate PA recovery from surface of the
skin, previous experiments, performed immediately after
the application of the preparations, were conducted. The
data showed that PA recovery from o/w, w/o/w emulsions
and ointment was of 95.1% ± 2.5, 92.9% ± 1.8 and 62.8%
± 1.1 (n=3), respectively. In order to improve PA recovery
rate from lipophillic ointment, a first washing was
performed with 500 µL of chloroform and then as
described for the other formulations (Extranâ and water).
Skin uptake and permeation data of PA from emulsions
and ointment through stripped skin are redrawn in Table II
and Figure 2, respectively. Mass balance ranged from 92
to 98%. Skin permeation of PA from o/w emulsion (87.1%
± 3.9) was 5 times higher than that observed for w/o/w
multiple emulsion (14.7% ± 0.5) and ointment (16.6% ±
0.1). Greater efficacy of the o/w emulsion for delivering
FIGURE 1 - In vitro release of PA from o/w, w/o/w and w/o/wPA emulsions across cellulose acetate membrane. The
w/o/wPA multiple emulsion contains half of the PA amount into external aqueous phase. The formulations containing 1%
w/w of PA were applied (500 mg-infinite dose) over synthetic membranes mounted in Franz cells. The expressed values
correspond to the mean value ± SD (n=3).
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PA might be due to higher concentration of the drug in
external phase and/or to rapid increase in thermodynamic
activity due to evaporation of water. Changes in
thermodynamic activity of the drug, through evaporation of
a volatile vehicle, can often be a significant factor in topical
delivery (Chiang et al., 1989; Tata, Flynn, Weiner, 1995).
There is a good correlation between the permeation
and release data for the o/w emulsion and multiple
emulsion. Therefore, release and skin permeation of PA
from o/w emulsion were higher than those observed for
multiple emulsion, despite of differences in experimental
protocols (infinite and finite dose).
An analysis of Figure 2 demonstrates that flux of PA
from w/o/w emulsion and ointment already declines when
only 14 to 16% of the applied dose has been permeated.
For the multiple emulsion, this phenomenon could be
attributed to depletion of PA in the external aqueous phase.
For the ointment, this can be explained by permeation of a
small fraction of PA which was initially solubilized in this
preparation. These results suggest that the release of a
small fraction of PA from both formulations was
associated to a low skin penetration.
Since the skin permeation was greater from o/w
emulsion in comparison with other preparations, a higher
concentration of PA into skin could be expected. However,
surprisingly, PA uptake into stripped skin from o/w emulsion
was lower than that observed for w/o/w emulsion (Table II).
This can be explained by high depletion of the PA
concentration in donor compartment, once 87% of the applied
dose have been permeated from o/w emulsion after 24 hours.
FIGURE 2 - In vitro skin permeation of PA from o/w, w/o/w emulsions and ointment through dorsal skin excised from
hairless mice in partial absence of stratum corneum. The formulations containing 1% w/w of PA were applied (50 mg-
finite dose) over skin biopsies mounted in Franz cells. Each point represents average (n =3) ± SD.
TABLE II - Distributiona of PA (% dose applied), into stripped skin, after 24 hr
Formulations Permeation Skinb Surface wash Total recovery(%)
o/w emulsion 87.1 ± 3.9 1.1 ± 0.1 9.6 ± 1.7 97.9
w/o/w emulsion 14.7 ± 0.5 1.7 ± 0.2 75.2 ± 1.9 91.5
Ointment 16.6 ± 0.1 0.9 ± 0.1 74.3 ± 2.7 91.7
aformulations containing 1% w/w of PA were applied (50 mg-finite dose) over stripped skin biopsies from hairless mice
mounted in Franz diffusion cells; The SC was removed by stripping 5 times the skin; bepidermis + dermis; the expressed
values correspond to the mean value ± SD (n=3).
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Skin uptake and permeation of PA through intact skin
from tested preparations are redrawn in Table III. The mass
balance ranged from 91 to 100%. PA permeation was not
detectable and below of detection limit. As expected, PA
permeation through stripped skin was higher than that
observed for intact skin. PA uptake into intact skin from o/
w emulsion (0.9% ± 0.1) was about 3 and 10 times higher
than that observed for w/o/w multiple emulsion (0.3% ± 0.1)
and ointment (0.1% ± 0.1), respectively (Table III).
Improved topical delivery of PA from o/w emulsion can be
attributed to thermodynamic activity higher than that
observed for other formulations, as discussed earlier. Total
deposition (skin uptake) and skin permeation of lactic acid
into or through porcine skin, determined using a finite dose,
was in the following order: o/w > w/o/w > w/o emulsions
(Sah, Mukherjee, Wickett, 1998).
Although it has not been possible to evaluate skin
permeation of PA through the intact skin, our studies
conducted with stripped skin, a model that may be closer
to what is observed in cutaneous leishmaniasis, showed
significant differences among formulations. Our findings
are in good agreement with those previously reported
(Stone et al., 1968), in which the percutaneous absorption
of gentamycin, an antibiotic structurally related to PA,
from water-miscible bases was greater and faster than
from ointment bases.
In conclusion, release of PA from o/w emulsion was
faster than from w/o/w emulsion. PA release from w/o/wPA
multiple emulsion containing half of the PA amount in the
external aqueous phase was intermediate. Skin uptake and
permeation of PA from o/w emulsion were higher than
those observed for w/o/w emulsion and ointment. An
important consideration in cutaneous leishmaniasis is the
skin condition. Topical formulations may be applied either
to open lesions that have lost SC barrier property or to
thickened lesions that represent an additional barrier to
absorption (Garnier, Croft, 2002). Thus, our findings
suggest that a hydrophilic vehicle (o/w emulsion) could be
an interesting alternative to improved topical delivery of PA
in both conditions. Additional studies are required to
evaluate the influence of skin permeation enhancers
incorporated in this vehicle.
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RESUMO
Influência da forma farmacêutica (emulsão múlti-
pla A/O/A, emulsão O/A e pomada) sobre a
permeação e retenção cutânea da paromomicina
Pomadas contendo paromomicina (PA) são utilizadas
no tratamento tópico da leishmaniose cutânea. Embora
a influência do veículo seja crucial para otimização de
formulações contendo PA, este aspecto não tem sido
investigado experimentalmente. Neste estudo, nós ava-
liamos a influência do tipo de formulação [emulsões
óleo-em-água (o/a), múltipla água-em-óleo-em-água
(a/o/a) e pomadas] sobre a liberação e permeação
cutânea in vitro da PA e os experimentos foram condu-
zidos sobre membranas de acetato de celulose e
biópsias de pele de camundongos glabros, respectiva-
mente. A liberação de PA a partir da emulsão o/a
(51,7% da dose aplicada) foi mais rápida do que
aquela observada a partir da emulsão múltipla a/o/a
(3,0% da dose aplicada). A permeação cutânea da PA
a partir da emulsão o/a (87,1% ± 3,9), através da pele
sem estrato córneo, foi 5 a 6 vezes mais alta do que
aquela observada para a emulsão múltipla a/o/a
(14,7% ± 0,5) e pomada (16,6% ± 0.1), respectivamen-
te. A permeação da PA através da pele normal foi
desprezível para todas as formulações avaliadas.
Nesta condição, a retenção cutânea a partir da
emulsão o/a (0,9% ± 0,1) foi maior do que aquela
TABLE III - Distributiona of PA (% dose applied), into normal skin, 24 hr after application of the formulations
Formulations Permeation Skinb Surface wash Total recovery(%)
o/w emulsion NDc 0.9 ± 0.1 99.5 ± 2.6 100.4
w/o/w emulsion ND 0.3 ± 0.1 91.0 ± 1.7 91.3
Ointment ND 0.1 ± 0.1 98.5 ± 7.7 99.1
aformulations containing 1% w/w of PA were applied (50 mg-finite dose) over intact skin biopsies from hairless mice
mounted in Franz diffusion cells; bepidermis + dermis; cno detected.
The expressed values correspond to the mean value ± SD (n=3).
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observada para a emulsão múltipla (0,3% ± 0.1) e
pomada. Esses resultados sugerem que um veículo
hidrofílico seria uma alternativa interessante para
aumentar o transporte e a permeação cutânea da PA.
UNITERMOS: Paromomicina. Permeação cutânea.
Emulsões. Pomadas. Leishmaniose cutânea.
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